Tag: disease management

The global medical community is mourning the loss of Professor Martin O. Savage, Emeritus Professor of Pediatric Endocrinology at the William Harvey Research Institute, Barts and The London School of Medicine & Dentistry, Queen Mary University of London, who passed away on February 24, 2026. A figure of immense international stature, Professor Savage was recognized…

The United States Congress has officially passed a comprehensive funding bill for the Department of Health and Human Services (HHS) for fiscal year (FY) 2026, marking a significant legislative milestone for the biomedical research community. The final appropriations package includes an increase of approximately $415 million for the National Institutes of Health (NIH), a move…

The clinical landscape of metabolic medicine is undergoing a seismic shift as glucagon-like peptide-1 receptor agonists (GLP-1RAs), initially developed to manage type 2 diabetes, demonstrate efficacy far beyond glycemic control and generalized weight loss. Recent investigations published across various Endocrine Society journals suggest that these agents, particularly semaglutide, are multifaceted tools capable of altering sensory…

A landmark study published in The Journal of Clinical Endocrinology & Metabolism (JCEM) has provided definitive evidence linking obesity and high blood pressure directly to the development of vascular-related dementia. By utilizing a sophisticated genetic analysis known as Mendelian randomization, researchers have moved beyond mere correlation, establishing that a high Body Mass Index (BMI) is…

The Endocrine Society, a premier global organization representing over 18,000 professionals in the field of hormone research and clinical endocrinology, has unveiled a comprehensive suite of initiatives designed to bolster the endocrine research community. Amidst a shifting landscape of scientific funding and institutional support, the Society is intensifying its efforts to assist researchers at every…

The Endocrine Society has officially launched its January 2026 programming, marking the beginning of the year with a comprehensive tribute to the global leaders of hormone research and clinical practice. This month’s initiative, headlined by the announcement of the 2026 Laureate Award winners, serves as a cornerstone for the endocrine community, highlighting the intersection of…

The landscape of metabolic medicine underwent a significant transformation in early January 2026 as the 25 mg oral formulation of semaglutide, marketed under the brand name Wegovy, officially became available across the United States. This launch follows a rigorous review process by the U.S. Food and Drug Administration (FDA), which granted approval for the once-daily…

The Endocrine Society has officially announced the commencement of its Rare Endocrine Disease (RED) Fellows Program, a specialized educational initiative designed to provide early-career physicians with the advanced knowledge and practical clinical skills essential for managing complex, low-prevalence hormonal disorders. Developed in strategic partnership with the National Organization for Rare Disorders (NORD), the program seeks…

Research conducted at the University of Victoria (UVic) has established a significant correlation between a woman’s insulin levels during midlife and the subsequent timing, duration, and severity of menopausal symptoms, including hot flashes, night sweats, and cold sweats. The study, published in the prestigious peer-reviewed Journal of Clinical Endocrinology & Metabolism, suggests that metabolic health…

The pharmaceutical landscape is currently witnessing a transformative era defined by the meteoric rise of glucagon-like peptide-1 receptor agonists (GLP-1RAs). While these medications have been utilized for decades in the management of type 2 diabetes and short bowel syndrome, their recent pivot toward treating obesity has turned them into household names, including Ozempic, Wegovy, and…